Horizon Investment Services LLC Has $1.21 Million Stock Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Horizon Investment Services LLC lowered its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 11.9% during the fourth quarter, Holdings Channel reports. The fund owned 2,332 shares of the medical research company’s stock after selling 316 shares during the period. Horizon Investment Services LLC’s holdings in Thermo Fisher Scientific were worth $1,213,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of TMO. Howard Capital Management Group LLC raised its position in shares of Thermo Fisher Scientific by 0.5% during the third quarter. Howard Capital Management Group LLC now owns 54,575 shares of the medical research company’s stock worth $33,759,000 after acquiring an additional 286 shares during the last quarter. Principal Financial Group Inc. raised its holdings in Thermo Fisher Scientific by 22.1% during the 3rd quarter. Principal Financial Group Inc. now owns 1,247,838 shares of the medical research company’s stock worth $771,876,000 after purchasing an additional 225,568 shares during the last quarter. Isthmus Partners LLC bought a new position in shares of Thermo Fisher Scientific in the 3rd quarter valued at about $353,000. Martingale Asset Management L P grew its position in shares of Thermo Fisher Scientific by 654.5% during the 3rd quarter. Martingale Asset Management L P now owns 8,382 shares of the medical research company’s stock worth $5,185,000 after buying an additional 7,271 shares during the period. Finally, Rockefeller Capital Management L.P. raised its stake in shares of Thermo Fisher Scientific by 0.8% during the third quarter. Rockefeller Capital Management L.P. now owns 244,851 shares of the medical research company’s stock worth $151,432,000 after buying an additional 1,966 shares during the last quarter. 89.23% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $516.67, for a total transaction of $5,166,700.00. Following the sale, the chief executive officer now owns 115,174 shares in the company, valued at approximately $59,506,950.58. This trade represents a 7.99 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Stephen Williamson sold 9,825 shares of the company’s stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total value of $5,753,421.75. Following the sale, the chief financial officer now owns 27,296 shares of the company’s stock, valued at $15,984,264.64. The trade was a 26.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 23,900 shares of company stock valued at $13,106,062 over the last quarter. 0.34% of the stock is owned by company insiders.

Thermo Fisher Scientific Trading Down 2.3 %

Shares of Thermo Fisher Scientific stock opened at $499.75 on Friday. The stock has a market cap of $188.53 billion, a P/E ratio of 30.23, a P/E/G ratio of 2.99 and a beta of 0.79. Thermo Fisher Scientific Inc. has a 12-month low of $493.30 and a 12-month high of $627.88. The business’s 50 day moving average is $541.60 and its 200-day moving average is $552.80. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.59.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Thursday, January 30th. The medical research company reported $6.10 earnings per share for the quarter, topping the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. Equities research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, April 15th. Investors of record on Friday, March 14th will be given a $0.43 dividend. The ex-dividend date is Friday, March 14th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.34%. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.41%.

Analyst Ratings Changes

A number of analysts have commented on TMO shares. Morgan Stanley lifted their target price on shares of Thermo Fisher Scientific from $647.00 to $678.00 and gave the stock an “overweight” rating in a report on Friday, January 31st. Royal Bank of Canada set a $693.00 price objective on Thermo Fisher Scientific in a report on Friday, January 31st. Bank of America decreased their target price on Thermo Fisher Scientific from $675.00 to $660.00 and set a “buy” rating for the company in a research report on Friday, December 13th. StockNews.com raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Tuesday, January 14th. Finally, Scotiabank upped their target price on shares of Thermo Fisher Scientific from $605.00 to $650.00 and gave the company a “sector perform” rating in a research note on Monday, February 3rd. Four equities research analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $653.23.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.